Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

The BTK inhibitor demonstrated better results than Imbruvica, a standard of care treatment in CLL

- PMLiVE

Meeting healthcare’s rising challenges

The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential

- PMLiVE

Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality

By Stephen Jones, Heather Bennett and Agustin Ramirez

- PMLiVE

SCIRIS ACQUIRES SOURCE HEALTH ECONOMICS

Global healthcare communications company SCIRIS is delighted to announce the acquisition of UK-based Source Health Economics – an agency specialising in health economics and outcomes research (HEOR).The development is the...

Porterhouse Medical Group

- PMLiVE

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

The FDA said there was not enough trial data from patients who were treated for at least a year

- PMLiVE

BeiGene’s Brukinsa granted two new marketing authorisations by MHRA

The BTK inhibitor is now approved for chronic lymphocytic leukaemia and marginal zone lymphoma

- PMLiVE

Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis

Amvuttra is given every three months, compared to every few weeks with existing therapies

How to Increase Engagement During Virtual Events

Tip #8 - Do you make sure to have a host for all your virtual events? Check our top 10 tips to increase engagement during virtual events: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/

Impetus Digital

- PMLiVE

EU to revise pharmaceuticals law amid antibiotic shortages

The early upsurge in respiratory infections has led to a sudden increase in demand for antibiotics

- PMLiVE

Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE

Ninlaro with lenalidomide and dexamethasone improved clinical outcomes

- PMLiVE

Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer

Tecentriq in combination with Avastin significantly improved recurrence-free survival

- PMLiVE

Report gives insights to address gaps in HCP engagement

How does Pharma-HCP engagement need to evolve in today's digital landscape?

EPG Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links